PATH vs PLSE · P/E 19, rev $1.61B vs $1.03B cap
Uipath Inc (PATH) versus Pulse Biosciences Inc (PLSE) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Pulse Biosciences Inc (PLSE) is a medical instruments & supplies company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PLSE revenue for 2024-12-31 was $0. Net income was -$53.6M. PLSE currently screens at market cap $1.03B.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PLSE currently screens at market cap $1.03B.
Not investment advice. Open the PATH and PLSE stock pages for the full models.
Not investment advice.